Nasdaq Biotechnology Ishares ETF (IBB)

Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.

As AI stocks face volatility, capital is rotating into biotech, industrials, utilities, consumer staples, and dividend ETFs showing relative strength.

SpaceX IPO buzz faded as AI volatility, hotter inflation, and a shortened trading week shifted investor focus toward earnings season

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

As Incyte has considerably outperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Moderna has notably outperformed the broader market over the past year, yet Wall Street analysts maintain a cautious outlook about the stock’s prospects.

Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.

Although Bio-Techne has underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.